MedTrace Logo

Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema

NCT02399657 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-04-06

No results posted yet for this study

Summary

A Single Arm, Single Dose Study to Evaluate the Effect of intravitreal dexamethasone implant (Ozurdex®) on hard exudates of diabetic macular edema.

Conditions

Interventions

DRUG

Intravitreal dexamethasone 0.7mg implant

Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Inje University

    lead OTHER

Principal Investigators

  • Hyun Woong Kim, M.D. · Inje University

  • Ji Eun Lee, M.D. · Pusan National University Hospital

  • Joo Eun Lee, M.D. · Inje University Haeundae Paik Hospital

  • Woo Jin Jeung, M.D. · Dong-A University Hospital

  • Sang Joon Lee, M.D. · Kosin University Gospel Hospital

  • In Young Chung, M.D. · Gyeongsang National University Hospital

  • Jae Pil Shin, M.D. · Kyungpook National University Hospital

  • Woo Hyok Chang, M.D. · Yeungnam University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02399657 on ClinicalTrials.gov